Lincoln Pharmaceuticals FY26: ₹671 Cr Revenue, 14.5x P/E, and a Cepha Block That Just Found Its Footing

General information and entertainment, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Consult a registered adviser before acting.

1 — At a Glance

Lincoln Pharmaceuticals closed FY26 with consolidated revenue of ₹671 Cr, up 7.7% year-on-year. Net profit came in at ₹87.89 Cr, growing 6.7% over FY25’s ₹82.35 Cr. On paper, that’s steady. Under the surface, Q4 FY26 PAT of ₹11.63 Cr landed almost exactly where Q4 FY25 did — ₹11.58 Cr — making the final quarter a 0.43% growth achievement that management, to their credit, attributed to “war and global scenario” rather than something more mundane.

The annualised EPS for FY26 stands at ₹43.88. The market, at the referenced price of ₹637.80 (prices referenced are not live), pays 14.5x those earnings. Against an industry P/E of 31.7, that gap has a story inside it — whether the story is discount, distrust, or indifference is a question the numbers keep raising without resolving.

The balance sheet holds ₹32.66 Cr in cash and ₹208.54 Cr in investments against ₹4.42 Cr of debt. The Cephalosporin block is generating revenue. Health Canada approved six dosage-form lines. And working capital days ballooned from 121 to 239 in one year.

That last number deserves its own chair at the table.

2 — Introduction

Lincoln Pharmaceuticals Ltd, incorporated in 1979 and publicly listed on BSE (531633) and NSE (LINCOLN), is an Ahmedabad-based pharmaceutical manufacturer with two production sites — Khatraj, Gujarat (EU-GMP, TGA, WHO-GMP certified) and Mehsana, Gujarat (WHO-GMP, BOMRA certified).

The company derives roughly 60-65% of revenue from exports across 60+ countries, spanning Africa, Latin America, Southeast Asia, and regulated markets like Canada. The domestic business runs through 600+ field force representatives across 26 states.

FY26 was a year of gradual construction. The Cephalosporin block at Mehsana — a multi-year capex project — crossed breakeven and contributed approximately ₹45 Cr in its first operational year. A dedicated R&D centre was acquired (a building purchased, operational timeline of 2–2.5 months as of the February 2026 concall). Health Canada expanded its approved manufacturing scope to six dosage-form lines following a January 2026 inspection. EU reinspection, which gates the European business, was awaiting scheduling as of Q3.

The company’s stated ambition: ₹1,000 Cr revenue by FY28, a target management described as “still sticking to” with a possible 5-6 month slippage. At FY26’s ₹671 Cr, the arithmetic requires approximately 14% compounded growth for two years — or, as management guided, 12-18% per annum.

Crisil reaffirmed the group’s CRISIL A/Stable/CRISIL A1 rating in January 2026, citing promoter experience, established market position, and healthy financial risk profile. The rating report noted ₹141 Cr in loans and advances extended to affiliates and individuals — up from ₹104 Cr a year prior — as a monitorable item.

3 — Business Model: WTF Do They Even Do?

Lincoln makes pills, capsules, injectables, syrups, and ointments — the full pharmaceutical repertoire, spanning 15 therapeutic areas and over 1,700 registered products. Another 700 are in the pipeline, patiently waiting their turn like a well-organised queue that the registration system has not yet gotten around to.

The therapeutic spread is impressively eclectic. Anti-infectives lead the revenue mix at roughly 30%, followed by musculoskeletal (12%), respiratory (8%), parasitology (7%), cardiovascular (6%), and alimentary tract (6%). Then there is an “Others” bucket at 29% — a number that, if it were a job title, would read: “miscellaneous contributions from fourteen other departments.”

The domestic business is a branded generics play, led by field-force-driven promotion. Key brands include Tinnex (ENT; management claims brand leadership in the segment for “buzzing ears”), Trixon, Vivian, and Mobyle. The company employs 600+ medical representatives nationally.

The export business, which contributes 60-65% of revenue, is a B2B model. Lincoln does not own warehouses or distribution entities abroad — a deliberate choice to avoid local currency complications, collections risk, and “local issues” in overseas markets. Instead, the company deploys country managers who track demand down to the B2C level through partner channels, while the invoicing stays clean and dollar-denominated.

The regulated-markets chapter is new and genuinely interesting. Canada is operational — approximately $3-5 million in revenue, with 15-17 products commercialised and a pipeline of 23-25 CDMO/CMO projects in progress. The Health Canada inspection in January 2026 approved tablets, capsules, ointments, sachets, dry syrup, and liquid syrup lines — six in total, which management called “open to all markets” as an SRA credential.

Australia (TGA) hit a snag when an acquisition-based MA transfer strategy failed. The company has reset to filing its own dossiers, implying roughly a one-year delay. Europe is audit-gated; the QP has audited, and the final reinspection was expected in May-June 2026.

Then there is the Cephalosporin block. A dedicated cephalosporin manufacturing line at Mehsana, now commercial, generated approximately ₹45 Cr in FY26 and is guided toward ₹90-100 Cr in FY27. Management’s longer-term aspiration: ₹150 Cr from this block. The math of whether that aspiration and a ₹1,000 Cr total target coexist comfortably without a new facility or acquisition is a question the company’s capex plans will need to answer.

The business is, at its core, a well-run generics exporter with a branded domestic franchise grafted on top, now making a serious attempt at the regulated-market tier — which, if it works, changes the margin conversation materially.

4 — Financials Overview

Figures are consolidated, in ₹ crore.

Quarterly Snapshot — Latest Quarter: Mar 2026 (Q4 FY26)

The revenue line recovered well — Q4 FY26 is the highest quarterly revenue in the dataset at ₹187.28 Cr. The profit line did not keep pace. Operating profit declined 7% year-on-year because